A Pragmatic view of Preclinical In-vivo Imaging Market

Preclinical in-vivo imaging – Meaning and a brief summary

Preclinical in-vivo imaging is a visualization technology used on living animals or living organisms to understand the mechanisms of disease for research purposes especially in drug development. Preclinical in-vivo imaging is in vogue for more than two decades with many studies have relied on in vivo imaging as a method to quantify treatment response and gain early insights on drug or on treatment efficacy. Preclinical imaging is playing a crucial role in translational research studies that are aimed at improving understanding of the mechanisms of disease thereby developing therapeutic strategies.

Advanced imaging technologies are providing biomedical researchers with non-invasive, in-vivo assessments of alterations at the organ, tissue, cell or molecular level in animal models of disease. In-vivo imaging of small animals (especially mice) is increasingly deployed across the drug development processes particularly in the oncology/cancer therapeutic area.

The most used imaging techniques or modalities that are currently in use are optical (bioluminescence and fluorescence), magnetic resonance imaging (MRI) and positron emission tomography (PET) and single photon emission tomography (SPECT) in the global preclinical in-vivo imaging market.

In-vivo imaging is increasingly being deployed across the drug development process with applicability in target identification, compound optimization, and pre-Phase I study. The preclinical in-vivo imaging industry in recent decades has undergone vast technological advances due to industry consolidation and changes in government funding and support for research studies across the globe.

Benefits of preclinical in-vivo imaging techniques – An overview

In-vivo imaging is an ideal application for investigating the real benefits of the use of compounds in drugs when used for a particular treatment of a disease. One of the benefits of preclinical in-vivo imaging technique allows for continuous measurements in live animals models over the course of treatment. However, imaging is more beneficial in brain tumor studies and in the field of oncology/cancer treatment.

Global preclinical in-vivo imaging market – Brief Statistics

Global preclinical in-vivo imaging was worth the US $1.49 billion in 2013 with the market expected to reach over $2.1 billion or more by the end of 2020 with a CAGR of 9.1% for the forecast period from 2014 to 2020. During 2013, micro-MRI device accounted for 31% share in the global imaging market delivering morphological pictures with excellent spatial resolution and contrast. Technological developments such as ‘Aspect M2’ are being used for drug development without cost, complexity and technical burden of traditional MRI systems.

Click to request sample of the report

The development of multimodal systems is transforming research practice that is facilitating the use of complementary imaging techniques to improve understanding of disease progression and drug efficacy. Enhanced camera capabilities in preclinical imaging equipments are bringing new level of sensitivity, speed, and versatility to non-invasive procedures that are enabling researchers to discover important biological mechanisms in disease to inform about treatment options and in monitoring of disease patterns.

Segmentation of preclinical in-vivo imaging market – A survey report

The global pre-clinical in-vivo imaging market is divided into segments such as Modality and Reagents. Under the Modality segment – the preclinical in-vivo imaging market is sub divided into seven major segments such as optical imaging, nuclear imaging, magnetic resonance imaging (MRI), micro-MRI, micro-CT, single photon emission tomography (SPECT),  positron emission tomography (PET), magnetic particle imaging (MPI) etc. The MRI and PET are vastly used in preclinical imaging.

Under the Reagents segment – the global preclinical in-vivo imaging market as per reputed market research reports is classified into fluorescent imaging reagents, bioluminescent imaging reagents, PET radioactive tracers, MRI contrasting reagents, X-ray CT contrast reagents and ultrasound contrast reagents. The end users of preclinical in-vivo imaging market are pharmaceutical companies, biotech companies, and drug discovery institutions or firms.

In terms of geographical segment – North America dominates the preclinical in-vivo imaging market because of rapid adoption and rising Research and Development activities in preclinical in-vivo imaging technology. In addition, the growing number of cancer, cardiovascular diseases in this region is the major cause of using preclinical in-vivo imaging devices for diagnostic purposes.

Europe is the second largest market for preclinical imaging that can be attributed to growing healthcare awareness among the people of this region. The major or key players operating in this market include – Aspects Imaging, Mediso Ltd, FUJIFILM Holdings America Corporation, Mediso Ltd and others. Finally, it can be observed that the rising global demand for efficacious, inexpensive medicines and technological advances are aiding towards the growth of global preclinical in-vivo imaging market.

Share this post:

Recent Posts

Leave a Comment

− 6 = 3